a UT Health San Antonio Long School of Medicine , San Antonio , TX , USA.
b Departments of Dermatology, Pathology and Department of Social Sciences & Health Policy Wake Forest School of Medicine , Center for Dermatology Research , Winston-Salem.
Expert Opin Investig Drugs. 2018 Nov;27(11):931-939. doi: 10.1080/13543784.2018.1533550. Epub 2018 Oct 19.
Psoriasis is a common immune disorder for which there are many FDA-approved therapies. Older oral drugs had limited efficacy and considerable side effects. Biologics have been a major advance but require self-administered injections, and many patients prefer oral options. Because many patients fear needles, oral drugs are a welcome option. This review provides an update on oral drugs in Phase II development for psoriasis.
A literature review was performed to identify these drugs by using search terms such as 'psoriasis', 'agents', 'drugs', and 'phase 2 development'. Baricitinib and KDO 25 are the oral drugs that appear to hold the most promise due to the balance they maintain between efficacy and adverse effects. If a RORγt inhibitor can be identified that has no hepatotoxicity, then that may be the most promising new oral treatment.
Several new oral psoriasis medications are currently being investigated. One major challenge remains medication cost and insurance coverage. Phase III studies are needed to determine efficacy and safety in large cohorts of psoriasis patients. An increase in the number of approved oral medications for psoriasis would mean more choice for psoriasis patients.
银屑病是一种常见的免疫性疾病，已有多种 FDA 批准的治疗方法。旧的口服药物疗效有限，副作用较大。生物制剂是一项重大进展，但需要自我注射，许多患者更喜欢口服选择。由于许多患者害怕针头，因此口服药物是一个受欢迎的选择。这篇综述提供了银屑病二期开发中口服药物的最新信息。
通过使用“银屑病”、“制剂”、“药物”和“二期开发”等搜索词进行文献回顾，以确定这些药物。巴利昔替尼和 KDO 25 是最有前途的口服药物，因为它们在疗效和不良反应之间取得了平衡。如果能发现一种没有肝毒性的 RORγt 抑制剂，那么它可能是最有前途的新型口服治疗药物。
目前正在研究几种新的银屑病口服药物。一个主要的挑战仍然是药物成本和保险覆盖范围。需要进行 III 期研究，以确定大量银屑病患者的疗效和安全性。批准用于银屑病的口服药物数量增加，意味着银屑病患者有更多的选择。
